Premier News

Medical and Regulatory Affairs

Europe’s New Trial Regulations: Quality VP to Address 2016 West and Wales Forum

DURHAM, N.C., April 05, 2016 – New European Union standards governing clinical research have significant implications for future drug trials. Nicky Dodsworth, Vice President, Quality Assurance, Risk & Compliance at Premier Research, will discuss these changes at the 2016 West and Wales Regional Forum on Innovation and Risk, April 21 in Milton Park, Oxfordshire, U.K. In...

Medical Director Authors Novel Look at Kleefstra Syndrome

DURHAM, N.C., April 1, 2016 — A paper authored by a Premier Research medical director takes an unprecedented look at motor function and behavior in adults and children with Kleefstra syndrome. Susanne Schmidt, M.D., Ph.D., and four Norwegian colleagues published their findings in the European Journal of Medical Genetics. The study of four male and...

Medical and Regulatory Affairs

Premier Research Names Lisa Pitt VP of Global Regulatory Affairs

DURHAM, N.C., March 15, 2016 — Premier Research announces the appointment of Lisa Pitt as Vice President of Global Regulatory Affairs. Joining Premier Research from the U.S. Food and Drug Administration, where she was a senior regulatory project manager, Dr. Pitt provides strategic guidance and oversees the company’s regulatory affairs service offerings in rare diseases...

Consulting

Starting a Novel Oncology Trial? A Lot Is at Stake, So Attend this February 24 Webinar

PHILADELPHIA, FEBRUARY 24, 2016 — There’s a lot to consider when investigating a novel and targeted oncology compound, and decisions you make early on can have profound and lasting implications. At a webinar on Wednesday, February 24, Premier Research will show how making sound decisions from the outset can improve your odds of long-term success....

Other

Premier Research Names Michael King Jolly Senior Vice President

PHILADELPHIA, February 02, 2016 — Premier Research announces the appointment of Michael King Jolly, Pharm.D., as Senior Vice President. In this newly created position, Dr. Jolly oversees drug development partnerships and develops innovative offerings for the company, a leader in clinical development for the biotech and specialty pharma sectors. With more than 30 years of...

Premier Research Names Paul Hallenbeck Executive Director for Oncology

PHILADELPHIA, December 17, 2015 — Premier Research announces the appointment of Paul Hallenbeck as Executive Director for Oncology. Dr. Hallenbeck has more than 20 years of experience in the biotech industry and expertise in all phases of oncology drug discovery, development, and commercialization, including work in complex, targeted biologics. Dr. Hallenbeck most recently served as...